On January 16, Johnson & Johnson (NYSE:JNJ) shared results from a new analysis of Phase 3 data showing that CAPLYTA ...
Depression is one of the most widespread mental health disorders worldwide, affecting approximately 4% of the global ...
A new study suggests that for people treating depression with common medications, the frequency of their yawning might track with how well they are healing. Published in the Journal of Psychiatric ...
WhiteSands Alcohol & Drug Rehab Orlando has published a new educational resource focused on treatment considerations during ...
A study from the University of Sydney's Brain and Mind Center reveals new clues as to why standard antidepressants fail for ...
AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient ...
For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major ...
One of the new members is Adam Urato, a maternal-fetal medicine doctor based in Massachusetts who has long fought against the ...
For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major depressive disorder. Early studies suggested promise, but enthusiasm faded after ...
What if the biggest driver of the antidepressant “effect” isn’t the drug, but your expectation? Learn why the placebo effect ...
Secretary Robert F. Kennedy Jr. announced the appointment of two new members to a key federal vaccine advisory panel, one of ...
The two newest appointees are obstetrician-gynecologists who at times have challenged broad medical consensus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback